Continuing its aggressive “Pivot to Growth” strategy, Parsippany-based Teva Pharmaceuticals announced Wednesday a definitive agreement to acquire Emalex Biosciences, a move that adds a promising, near-market therapy for pediatric Tourette syndrome (TS) to its neuroscience arsenal.
Under the terms of the deal, Teva will provide an upfront cash payment of $700 million, with Emalex shareholders eligible for an additional $200 million in commercial milestones plus royalties. The acquisition centers on ecopipam, a “first-in-class” drug that could offer the first new mechanism of action for Tourette patients in decades.
Most current treatments for Tourette syndrome target dopamine D2 receptors, which can often lead to significant side effects like weight gain and movement disorders. Ecopipam, however, is a selective dopamine D1 receptor antagonist.
Recent Phase 3 data for the drug demonstrated “statistically significant” results in reducing tics in children and adolescents. Crucially, the drug has already received Orphan Drug and Fast Track designations from the FDA, and Teva expects to submit a New Drug Application (NDA) by the second half of 2026.
“This is a prime example of our Pivot to Growth strategy in action,” Richard Francis, president and CEO of Teva said. “There is a real unmet need in Tourette syndrome, and families deserve additional options that can help manage symptoms while minimizing side effects.”
The acquisition reinforces Teva’s U.S. headquarters in Parsippany as a central hub for the company’s innovative medicine pipeline. By folding Emalex—a Chicago-based firm founded by Paragon Biosciences—into its operations, Teva is leveraging its massive global scale to bring specialized treatments to market faster.
Key financial details:
- Upfront Payment: $700 million (funded via cash on hand).
- Potential Milestones: $200 million.
- Target Closing: Q3 2026.
- NDA Submission: Anticipated 2H 2026.
Tourette syndrome typically begins in early childhood, with symptoms peaking during the school-age years. For many families, current medications are a trade-off between tic control and debilitating side effects.
Eric Messner, CEO of Emalex, noted that the partnership with Teva is the “fastest way” to reach these patients. “Teva’s global scale and neuroscience leadership position will help ecopipam reach patients as quickly and broadly as possible,” Messner stated.
Despite the large cash outlay, Teva leadership told investors during today’s Q1 2026 earnings call that the company remains on track to meet its 2027 financial targets. The firm intends to mitigate any near-term margin dilution, viewing the acquisition as a “capital-efficient” way to secure a high-value, innovative asset.
